marimastat has been researched along with paclitaxel in 9 studies
| Studies (marimastat) | Trials (marimastat) | Recent Studies (post-2010) (marimastat) | Studies (paclitaxel) | Trials (paclitaxel) | Recent Studies (post-2010) (paclitaxel) |
|---|---|---|---|---|---|
| 215 | 28 | 53 | 31,874 | 5,729 | 15,395 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (11.11) | 18.2507 |
| 2000's | 4 (44.44) | 29.6817 |
| 2010's | 4 (44.44) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Neijt, JP | 1 |
| Barrett, M; Burnitz, MC; Dipierro, C; Eto, M; Gibson, JJ; Myers, C; Phelps, C; Read, P; Somlyo, AP; Somlyo, AV | 1 |
| Heinemann, V | 1 |
| Goodin, S; Gounder, M; Lin, Y; Medina, M; Much, J; Musanti, R; Orlando, T; Pennick, M; Rubin, E; Shih, W; Toppmeyer, DL; Vyas, V | 1 |
| Anderson, IC; Eder, JP; Goffin, JR; Johnson, BE; Lynch, TJ; Shapiro, GI; Shipp, M; Skarin, AT; Supko, JG | 1 |
| Han, X; He, W; Lin, C; Lv, Y; Qin, C; Xin, X; Xu, C; Yang, L; Yang, X; Yin, L; Zhang, L; Zhao, X | 1 |
| He, W; Li, S; Lv, Y; Xiao, Q; Yin, L; Zhao, X; Zhu, L | 1 |
| He, W; Xiao, Q; Yin, L; Yuan, Y; Zhu, X | 1 |
2 review(s) available for marimastat and paclitaxel
| Article | Year |
|---|---|
[Cytostatic treatment of ovarian carcinoma].
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma; Chemotherapy, Adjuvant; Cisplatin; Female; Humans; Hydroxamic Acids; Ovarian Neoplasms; Paclitaxel; Protease Inhibitors; Trastuzumab | 1999 |
Gemcitabine in the treatment of advanced pancreatic cancer: a comparative analysis of randomized trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Biphenyl Compounds; Camptothecin; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Fluorouracil; Gemcitabine; Glutamates; Guanine; Humans; Hydroxamic Acids; Irinotecan; Organic Chemicals; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Pancreatic Neoplasms; Pemetrexed; Phenylbutyrates; Quinolones; Randomized Controlled Trials as Topic; Taxoids | 2002 |
2 trial(s) available for marimastat and paclitaxel
| Article | Year |
|---|---|
A phase I and pharmacologic study of the combination of marimastat and paclitaxel in patients with advanced malignancy.
Topics: Adult; Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Male; Middle Aged; Molecular Structure; Neoplasms; Paclitaxel | 2003 |
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Dose-Response Relationship, Drug; Drug Administration Schedule; Enzyme Inhibitors; Female; Hematologic Diseases; Humans; Hydroxamic Acids; Infusions, Intravenous; Lung Neoplasms; Male; Metabolic Clearance Rate; Metalloendopeptidases; Middle Aged; Nausea; Paclitaxel; Treatment Outcome | 2005 |
5 other study(ies) available for marimastat and paclitaxel
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Rho kinase and matrix metalloproteinase inhibitors cooperate to inhibit angiogenesis and growth of human prostate cancer xenotransplants.
Topics: Amides; Animals; Aorta, Thoracic; Cell Division; Cell Line; Drug Synergism; Enzyme Inhibitors; Humans; Hydroxamic Acids; In Vitro Techniques; Intracellular Signaling Peptides and Proteins; Male; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, SCID; Microscopy, Fluorescence; Myosin-Light-Chain Phosphatase; Neoplasm Transplantation; Neovascularization, Pathologic; Paclitaxel; Phosphoprotein Phosphatases; Phosphorylation; Prostatic Neoplasms; Protein Serine-Threonine Kinases; Pyridines; Rabbits; rho-Associated Kinases; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2003 |
Nanoplatform Assembled from a CD44-Targeted Prodrug and Smart Liposomes for Dual Targeting of Tumor Microenvironment and Cancer Cells.
Topics: Animals; Antineoplastic Agents, Phytogenic; Breast Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Drug Delivery Systems; Enzyme Inhibitors; Humans; Hyaluronan Receptors; Hyaluronic Acid; Hydroxamic Acids; Liposomes; MCF-7 Cells; Mice, Inbred BALB C; Paclitaxel; Prodrugs; Tumor Microenvironment | 2018 |
Targeting intracellular MMPs efficiently inhibits tumor metastasis and angiogenesis.
Topics: Angiogenesis Inhibitors; Animals; Caseins; Cell Line, Tumor; Drug Liberation; Female; Hyaluronic Acid; Hydroxamic Acids; Mammary Neoplasms, Experimental; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Mice; Mice, Inbred BALB C; Nanoconjugates; Neoplasm Metastasis; Neovascularization, Pathologic; Paclitaxel; Prodrugs; Protein Binding | 2018 |
A drug-delivering-drug strategy for combined treatment of metastatic breast cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Breast Neoplasms; Caseins; Cell Proliferation; Drug Combinations; Drug Delivery Systems; Enzyme Inhibitors; Female; Humans; Hydroxamic Acids; Lung Neoplasms; Matrix Metalloproteinases; Mice; Nanoparticles; Paclitaxel; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2018 |